NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered Retatrutide from HXNet? Mail in a sample (US only) and let us test it.

Test my supply
+4 more ↓
83%
Finnrick rating
#51 of 419 Retatrutide vendors
41 of 49 classifiable tests passed
customers 4.2★ (21)
methodology · Purity focus
Finnrick analysis · Retatrutide

HXNet retatrutide shows a mixed purity-focus record: recent samples pass, but history includes a Feb identity failure and fill misses of +54%, +51%, +42%, +38%, and -37%. Weigh the post-June pass streak against that volatility.

methodology →
vendor intelligence report
Vendor Intelligence Report: HXNet

Chinese registry snippets show the ChemicalBook anchor entity was cancelled before the current sales run. The report maps the HXTNT/LaraPharma channel shift, lookalike web infrastructure, and COA files that reuse third-party lab identifiers.

41 pages5 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.04
90%
14
2
Tirzepatide
$0.35
89%
52
3
Retatrutideselected
$0.60
83%
49
4
Semaglutide
$1.00
76%
5
6
BPC-157
$0.60
67%
10
7
PT-141
$0.50
64%
2
8
Cagrilintide
$1.76
62%
15
9
Tesamorelin
$1.80
54%
12
10
CJC-1295
-
49%
5
11
Sermorelin
-
49%
3
12
TB-500
$1.36
48%
6
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%11 Aug 2025: 67%11 Aug 2025: 69%14 Aug 2025: 70%21 Aug 2025: 74%30 Sep 2025: 79%4 Nov 2025: 82%4 Nov 2025: 78%11 Dec 2025: 79%13 Dec 2025: 80%13 Dec 2025: 81%13 Dec 2025: 83%1 Jan 2026: 84%1 Jan 2026: 85%7 Jan 2026: 86%15 Jan 2026: 87%15 Jan 2026: 88%19 Jan 2026: 88%22 Jan 2026: 89%22 Jan 2026: 89%26 Jan 2026: 90%26 Jan 2026: 91%26 Jan 2026: 88%26 Jan 2026: 88%11 Feb 2026: 85%11 Feb 2026: 86%16 Feb 2026: 83%16 Feb 2026: 80%18 Feb 2026: 81%18 Feb 2026: 81%18 Feb 2026: 79%22 Feb 2026: 77%2 Mar 2026: 77%3 Mar 2026: 78%4 Mar 2026: 79%6 Mar 2026: 79%6 Mar 2026: 80%29 Mar 2026: 80%28 Apr 2026: 81%30 Apr 2026: 81%8 May 2026: 82%21 May 2026: 82%27 May 2026: 80%2 Jun 2026: 81%4 Jun 2026: 81%13 Jul 2026: 82%20 Jul 2026: 82%24 Sep 2026: 82%12 Oct 2026: 83%13 Oct 2026: 83%15 Nov 2026: current 83%67%88%83%Aug 25Nov 26
Showing Retatrutide tests only
Peptide testing

Ordered Retatrutide from HXNet? Mail in a sample (US only) and let us test it.

Test my supply
HXNet Retatrutide test history
COA-backed lab tests
1-10 of 49

About HXNet test results from Finnrick

HXNet is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 12 peptides and 178 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible HXNet peptides in this dataset are Tirzepatide (52 tests), Semaglutide (5 tests) and BPC-157 (10 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 178 recent tests.

Corrections
No corrections.
Peptide testing

Ordered Retatrutide from HXNet? Mail in a sample (US only) and let us test it.

Test my supply